Literature DB >> 26788127

A comparison between plasmapheresis and intravenous immunoglobulin in children with Guillain-Barré syndrome in Upper Egypt.

Khaled Saad1, Ismail L Mohamad2, Mohamed A Abd El-Hamed3, Mostafa S K Tawfeek2, Ahmed E Ahmed4, Khaled A Abdel Baseer4, Ahmed S El-Shemy5, Amira A El-Houfey6, Diaa M Tamer2.   

Abstract

OBJECTIVE: The aim of our study is to assess the clinico-electrophysiological profile of children with Guillain-Barré syndrome (GBS) in Upper Egypt and to compare the efficacy of plasmapheresis versus other treatment modalities. PATIENTS AND METHODS: This was a retrospective study of children from January 2010 to October 2014 diagnosed as GBS. It included 62 cases.
RESULTS: Acute inflammatory demyelinating polyradiculoneuropathy (AIDP) was the most prevalent type of GBS in our locality. As regards the treatment, 32 cases received plasmapheresis while 30 patients received intravenous immunoglobulin. We found a significant decrease in the duration of hospitalization and a significant increase in the number of children with complete recovery in cases treated with plasmapheresis.
CONCLUSION: GBS is not uncommon in children of Upper Egypt, with AIDP the most prevalent type. Plasmapheresis is the best treatment modalities for GBS as it reduces the duration of hospital stay and hastens the recovery of those children.

Entities:  

Keywords:  Guillain–Barré Syndrome; children; intravenous immunoglobulin; outcome; plasmapheresis

Year:  2016        PMID: 26788127      PMCID: PMC4710103          DOI: 10.1177/1756285615610471

Source DB:  PubMed          Journal:  Ther Adv Neurol Disord        ISSN: 1756-2856            Impact factor:   6.570


  24 in total

1.  A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain-Barré syndrome.

Authors:  H C Diener; W F Haupt; T M Kloss; F Rosenow; T Philipp; S Koeppen; A Vietorisz
Journal:  Eur Neurol       Date:  2001       Impact factor: 1.710

2.  A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group.

Authors:  F G van der Meché; P I Schmitz
Journal:  N Engl J Med       Date:  1992-04-23       Impact factor: 91.245

Review 3.  Management of children with Guillain-Barré syndrome.

Authors:  S Agrawal; D Peake; W P Whitehouse
Journal:  Arch Dis Child Educ Pract Ed       Date:  2007-12       Impact factor: 1.309

Review 4.  The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review.

Authors:  Anita McGrogan; Gemma C Madle; Helen E Seaman; Corinne S de Vries
Journal:  Neuroepidemiology       Date:  2008-12-17       Impact factor: 3.282

Review 5.  Assessment of current diagnostic criteria for Guillain-Barré syndrome.

Authors:  A K Asbury; D R Cornblath
Journal:  Ann Neurol       Date:  1990       Impact factor: 10.422

6.  Intravenous immunoglobulin therapy for Guillain-Barré syndrome with IgG anti-GM1 antibody.

Authors:  S Kuwabara; M Mori; K Ogawara; T Hattori; S Oda; M Koga; N Yuki
Journal:  Muscle Nerve       Date:  2001-01       Impact factor: 3.217

7.  The concept and classification of Guillain-Barré syndrome and related disorders.

Authors:  R A Hughes
Journal:  Rev Neurol (Paris)       Date:  1995-05       Impact factor: 2.607

8.  Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  R A C Hughes; E F M Wijdicks; R Barohn; E Benson; D R Cornblath; A F Hahn; J M Meythaler; R G Miller; J T Sladky; J C Stevens
Journal:  Neurology       Date:  2003-09-23       Impact factor: 9.910

9.  A clinical and electrophysiologic survey of childhood Guillain-Barré syndrome.

Authors:  Pi-Lien Hung; Wen-Neng Chang; Li-Tung Huang; Song-Chei Huang; Ying-Chao Chang; Chin-Jung Chang; Chen-Sheng Chang; Kuo-Wei Wang; Ben-Chung Cheng; Hsueh-Wen Chang; Cheng-Hsien Lu
Journal:  Pediatr Neurol       Date:  2004-02       Impact factor: 3.372

10.  Treatment guidelines for Guillain-Barré Syndrome.

Authors:  A K Meena; S V Khadilkar; J M K Murthy
Journal:  Ann Indian Acad Neurol       Date:  2011-07       Impact factor: 1.383

View more
  4 in total

1.  Plasma exchange as a cost-effective option for treating Guillain-Barré syndrome.

Authors:  Eric J Buenz; Gareth J Parry; Annemarei Ranta
Journal:  Ther Adv Neurol Disord       Date:  2016-08-16       Impact factor: 6.570

Review 2.  Axonal variants of Guillain-Barré syndrome: an update.

Authors:  Pei Shang; Mingqin Zhu; Ying Wang; Xiangyu Zheng; Xiujuan Wu; Jie Zhu; Jiachun Feng; Hong-Liang Zhang
Journal:  J Neurol       Date:  2020-03-05       Impact factor: 4.849

3.  Intravenous Immunoglobulin for Severe Protracted Pediatric Guillain-Barre Syndrome: Is Single Dose Adequate?

Authors:  Priyanka Madaan; Prashant Jauhari; N M Shruthi; Biswaroop Chakrabarty; Sheffali Gulati
Journal:  Ann Indian Acad Neurol       Date:  2019 Jan-Mar       Impact factor: 1.383

4.  Initial Response and Outcome of Critically Ill Children With Guillain Barre' Syndrome.

Authors:  Hafez M Bazaraa; Hanaa I Rady; Shereen A Mohamed; Walaa A Rabie; Noha H ElAnwar
Journal:  Front Pediatr       Date:  2019-09-18       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.